Jefferies Financial Group Inc. Acquires 620,440 Shares of Xencor, Inc. $XNCR

Posted by Geri Gentry on May 25th, 2026

Jefferies Financial Group Inc. raised its holdings in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 620.4% in the 4th quarter, Holdings Channel reports. The firm owned 720,440 shares of the biopharmaceutical company’s stock after purchasing an additional 620,440 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Xencor were worth $11,030,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Primecap Management Co. CA lifted its position in shares of Xencor by 1.4% during the third quarter. Primecap Management Co. CA now owns 10,675,022 shares of the biopharmaceutical company’s stock worth $125,218,000 after purchasing an additional 147,700 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Xencor by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 7,165,450 shares of the biopharmaceutical company’s stock valued at $109,703,000 after buying an additional 61,692 shares during the period. Legal & General Group Plc increased its stake in shares of Xencor by 603.7% during the third quarter. Legal & General Group Plc now owns 1,273,000 shares of the biopharmaceutical company’s stock valued at $14,932,000 after buying an additional 1,092,095 shares during the period. UBS Group AG increased its stake in shares of Xencor by 51.4% during the third quarter. UBS Group AG now owns 1,175,267 shares of the biopharmaceutical company’s stock valued at $13,786,000 after buying an additional 399,071 shares during the period. Finally, Baker BROS. Advisors LP increased its stake in shares of Xencor by 64.4% during the third quarter. Baker BROS. Advisors LP now owns 1,102,106 shares of the biopharmaceutical company’s stock valued at $12,928,000 after buying an additional 431,675 shares during the period.

Insider Buying and Selling at Xencor

In other Xencor news, SVP Celia Eckert sold 3,244 shares of Xencor stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $11.25, for a total value of $36,495.00. Following the transaction, the senior vice president owned 78,685 shares in the company, valued at $885,206.25. The trade was a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bassil I. Dahiyat sold 14,870 shares of Xencor stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $11.25, for a total value of $167,287.50. Following the completion of the transaction, the chief executive officer owned 552,922 shares in the company, valued at $6,220,372.50. This trade represents a 2.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 44,020 shares of company stock worth $499,817 over the last quarter. Insiders own 4.76% of the company’s stock.

Xencor Price Performance

XNCR opened at $11.31 on Monday. The business’s 50-day moving average is $12.18 and its two-hundred day moving average is $13.42. Xencor, Inc. has a 1 year low of $6.92 and a 1 year high of $18.69. The firm has a market capitalization of $838.52 million, a PE ratio of -4.94 and a beta of 0.93.

Xencor (NASDAQ:XNCR – Get Free Report) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.96). Xencor had a negative net margin of 177.10% and a negative return on equity of 28.77%. The company had revenue of $4.52 million during the quarter, compared to analysts’ expectations of $27.86 million. During the same quarter last year, the firm earned ($0.66) EPS. Xencor’s revenue for the quarter was down 86.2% on a year-over-year basis. As a group, sell-side analysts expect that Xencor, Inc. will post -3.82 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on XNCR shares. Zacks Research lowered Xencor from a “hold” rating to a “strong sell” rating in a research note on Wednesday, May 6th. JPMorgan Chase & Co. raised their price target on Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a research note on Monday, May 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a research note on Friday, March 27th. Barclays raised their price target on Xencor from $26.00 to $27.00 and gave the company an “overweight” rating in a research note on Thursday, February 26th. Finally, Wall Street Zen lowered Xencor from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 9th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $24.50.

Check Out Our Latest Report on Xencor

Xencor Company Profile

(Free Report)

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.